FeedbackNow, the world leader in operational analytics for physical spaces, announced today their Series A round. The round was led by Motivate VC, Uncorrelated Ventures, and AI Growth Capital ...

GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY (Respiratory ...

2024.126294) The study conducted by researchers at the University of Michigan and the U.S. Centers for Disease Control and Prevention and published in the journal Vaccine, evaluated newly approved RSV ...

for infants and Arexvy for seniors—based on cost-effectiveness concerns. And while it has recommended listing of RSV vaccine Abrysvo This content is restricted to registered users only. If you have ...

[34][35][36][37][38][39] The world’s first respiratory syncytial virus (RSV) vaccine for older adults Arexvy is registered for use in Canada, Australia, the US, the UK, the European Union, Japan and ...

It is going to look a little bizarre, but there is a great reason behind the change… Nike have changed their logo on third kits to celebrate women's football. They explained their switch for ...

Advances in medical research have brought effective RSV vaccines to the market, such as Arexvy and Abrysvo. Neither is an mRNA vaccine, but both vaccines are indicated to prevent RSV in adults. The ...

Scottie Scheffler moved one step closer to pocketing the $25 million payout that comes with winning the 2024 FedEx Cup Playoffs by going 65-66 over the first 36 holes to maintain his spot atop the ...

A Reddit thread started Thursday titled, "What's wrong with the Facebook logo?" shows a blue lowercase "f" on a black background instead of a blue background with a white "f." Some users who have ...

The European Commission (EC) has authorised GSK’s Arexvy for active immunisation against lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults aged 50 to ...

The CDC recommends a single dose of either GSK’s AREXVY, Moderna’s mRESVIA or Pfizer’s ABRYSVO for all adults 75 years and older and adults between the ages of 60 to 74 who are at increased ...